Duality Theorems in Ergodic Transport

We analyze several problems of Optimal Transport Theory in the setting of Ergodic Theory. In a certain class of problems we consider questions in Ergodic Transport which are generalizations of the ones in Ergodic Optimization. Another class of problems is the following: suppose $\sigma$ is the shift acting on Bernoulli space $X=\{0,1\}^\mathbb{N}$, and, consider a fixed continuous cost function $c:X \times X\to \mathbb{R}$. Denote by $\Pi$ the set of all Borel probabilities $\pi$ on $X\times X$, such that, both its $x$ and $y$ marginal are $\sigma$-invariant probabilities. We are interested in the optimal plan $\pi$ which minimizes $\int c d \pi$ among the probabilities on $\Pi$. We show, among other things, the analogous Kantorovich Duality Theorem. We also analyze uniqueness of the optimal plan under generic assumptions on $c$. We investigate the existence of a dual pair of Lipschitz functions which realizes the present dual Kantorovich problem under the assumption that the cost is Lipschitz continuous. For continuous costs $c$ the corresponding results in the Classical Transport Theory and in Ergodic Transport Theory can be, eventually, different. We also consider the problem of approximating the optimal plan $\pi$ by convex combinations of plans such that the support projects in periodic orbits

Billing practices among us tobacco use treatment providers

and improving coordination between intensive therapies validated in research and "real-world" logistics.Objectives: The US Affordable Care Act (ACA) now requires almost all health insurance plans to cover tobacco use treatment (TUT), but TUT remains underutilized. Methods: We conducted an anonymous online survey of US TUT providers in 2016 regarding their billing practices. Results: Participants (n131) provided services primarily in medical and behavioral health settings and were from a variety of professions. Most provided intensive individual (>15 minutes per session) and/or group counseling. Although most reported that their organization accepted at least 1 form of insurance, only 34% reported that TUT services were billed, with about equal proportions endorsing billing under their own independent tax ID and "incident to" billing under a supervisor. Half of billers (52%) reported using at least 1 Current Procedural Terminology code. The most common codes were 99406 and 99407, but 18 unique codes were specified. Themes of qualitative responses (n101) included concern about how to initiate and sustain adequate reimbursement, and experiences with billing not being "worth" the time or effort. Conclusions: Overall, results demonstrate a need for providers, administrators, and billing managers to work collaboratively. Even with the ACA mandate, and consistent with prior reports, reimbursement rates may be inadequate for intensive counseling. Areas for advocacy include recognizing that TUT requires similar intensity, expertise, and reimbursement as other substance use disorders and chronic medical conditionsgiving Tobacco Treatment Specialists the ability to bill independentl

Moral courage in the workplace: moving to and from the desire and decision to act

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72135/1/j.1467-8608.2007.00484.x.pd

Velocity-space sensitivity of the time-of-flight neutron spectrometer at JET

The velocity-space sensitivities of fast-ion diagnostics are often described by so-called weight functions. Recently, we formulated weight functions showing the velocity-space sensitivity of the often dominant beam-target part of neutron energy spectra. These weight functions for neutron emission spectrometry (NES) are independent of the particular NES diagnostic. Here we apply these NES weight functions to the time-of-flight spectrometer TOFOR at JET. By taking the instrumental response function of TOFOR into account, we calculate time-of-flight NES weight functions that enable us to directly determine the velocity-space sensitivity of a given part of a measured time-of-flight spectrum from TOFOR

Relationship of edge localized mode burst times with divertor flux loop signal phase in JET

A phase relationship is identified between sequential edge localized modes (ELMs) occurrence times in a set of H-mode tokamak plasmas to the voltage measured in full flux azimuthal loops in the divertor region. We focus on plasmas in the Joint European Torus where a steady H-mode is sustained over several seconds, during which ELMs are observed in the Be II emission at the divertor. The ELMs analysed arise from intrinsic ELMing, in that there is no deliberate intent to control the ELMing process by external means. We use ELM timings derived from the Be II signal to perform direct time domain analysis of the full flux loop VLD2 and VLD3 signals, which provide a high cadence global measurement proportional to the voltage induced by changes in poloidal magnetic flux. Specifically, we examine how the time interval between pairs of successive ELMs is linked to the time-evolving phase of the full flux loop signals. Each ELM produces a clear early pulse in the full flux loop signals, whose peak time is used to condition our analysis. The arrival time of the following ELM, relative to this pulse, is found to fall into one of two categories: (i) prompt ELMs, which are directly paced by the initial response seen in the flux loop signals; and (ii) all other ELMs, which occur after the initial response of the full flux loop signals has decayed in amplitude. The times at which ELMs in category (ii) occur, relative to the first ELM of the pair, are clustered at times when the instantaneous phase of the full flux loop signal is close to its value at the time of the first ELM

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Effect of dietary lipid sources on the growth and body fatty acid composition of sea bass Dicentrarchus labrax L. 1758

This study was carried out in Yumurtalik Marine Research Station, University of Cukurova in Turkey. In this study was aimed to determine the effects of different levels of soybean oil and fish oil on growth and body fatty acid composition of sea bass (Dicentrarchus labrax). Initial mean body weights of test subjects were 4.80±0.25 g. The fish were housed within experimental, 2101 of experimental fiberglass tanks (20 fish/tank). Fish of all groups were fed on five different levels feed a 105 day period. The fish group fed with Diet 1 (12% Fish Oil = FO) followed by Diet 5 (12% Soybean Oil = SBO) showed the highest growth performance. In this study saturated, monounsaturated and polyunsaturated fatty acid changes in all groups were significant (p>0.05). On the basis of these results it can be concluded that soybean oil could be used as a partial dietary substitute for fish oil within compound feeds for sea bass. © Medwell Journals, 2008

Effects of dietary l-carnitine supplementation on growth, muscle fatty acid composition and economic profit of rainbow trout (Oncorhynchus mykiss) [L-carnitine'nin gökkuşagı alabalıgının (oncorhynchus mykiss) büyümesine ve kas yag asidi kompozisyonuna etkileri ve ekonomik yararlılıgı]

In this study, the effect of dietary L-carnitine on growth, proximate and muscle fatty acid compositions of rainbow trout (Oncorhynchus mykiss) were investigated. The fish were fed with diets containing 300 mg kg-1 L-carnitine (LC300), other group was fed with diets containing 600 mg kg-1 L-carnitine (LC600) and control group was not supplementary L-carnitine for 63 days. The weight gain of LC600 fed with L-carnitine supplemented was found to be 7.73% higher than in control group. Feed conversion ratio in LC600 (1.66) and LC300 (1.60) is better than in control group (2.00). L-carnitine supplemented groups would be lower cost of production than control. Economic conversion ratio (ECR) of LC300 (2.71 US.$kg-1) would represent a saving of 0.44 US.$ kg-1 compared to the control. L-carnitine administration did not affect proximate composition of muscle except for protein percent. Protein content of L-carnitine supplemented groups was higher than control group. Total saturated monounsaturated and polyunsaturated muscle fatty acid content increased by L-carnitine supplementation in rainbow trout. The results indicate that supplementation of 600 mg L-carnitine/kg diet is more effective on growth than the other L-carnitine supplementation level 300 mg kg -1 and control diet in commercial cage conditions. © Published by Central Fisheries Research Institute (CFRI) Trabzon, Turkey